相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Review
Neurosciences
Izabella B. Q. de Lima et al.
Summary: Despite the lack of understanding about the origin and mechanisms of Alzheimer's disease (AD), recent studies have shown that metabotropic glutamate receptors (mGluRs) in glial cells play a significant role in the establishment and progression of AD. However, the specific roles of different types of mGluRs vary depending on the cell type and brain region. Further investigation into the role of glial mGluRs in AD is crucial for future therapeutic strategies.
CURRENT NEUROPHARMACOLOGY
(2023)
Review
Neurosciences
Khaled S. Abd-Elrahman et al.
Summary: This review discusses the disruption of neuroglial homeostasis by β-amyloid and hyperphosphorylated tau, and their contribution to the pathophysiology of Alzheimer's Disease.
CURRENT NEUROPHARMACOLOGY
(2023)
Review
Neurosciences
Gabriela L. L. Martins et al.
Summary: Alzheimer's disease (AD) is a complex clinical condition with multifactorial origin that poses a major burden to health care systems worldwide. Both central and peripheral inflammation, particularly the activation of the NLRP3 inflammasome, has been implicated in AD. Dyslipidemia, as a risk factor for dementia, and its association with cholesterol and oxysterols are also speculated to be involved in AD pathology. This review explores the potential role of NLRP3 activation by nuclear receptors, mediated by oxysterols, as a pharmacological avenue in dementia.
CURRENT NEUROPHARMACOLOGY
(2023)
Review
Neurosciences
Bernardo H. M. Correa et al.
Summary: Calcium (Ca2+) is crucial for cellular regulation and cell survival, but disruptions in Ca2+ homeostasis can lead to cell death. Voltage-gated Ca2+ channels (VGCCs) are the main source of Ca2+ entry into cells, and their dysregulation has been implicated in Parkinson's disease (PD) and Huntington's disease (HD). This review focuses on the role of neuronal VGCCs in the pathogenesis and treatment of PD and HD, aiming to understand the neurodegenerative processes and identify potential therapeutic targets.
CURRENT NEUROPHARMACOLOGY
(2023)
Article
Neurosciences
Mi Yang et al.
Summary: Objective: To investigate the effects of antipsychotic medication on oxidative stress markers in patients with schizophrenia. Methods: A systematic review and meta-analysis were conducted following the PRISMA guidelines. Results: Antipsychotic treatment resulted in changes in oxidative stress markers in schizophrenia patients, with different effects observed in different blood samples. However, the quality of the published literature was poor, limiting the accuracy of the findings.
CURRENT NEUROPHARMACOLOGY
(2023)
Review
Neurosciences
Laila Asth et al.
Summary: This study investigates the potential of beta-caryophyllene (BCP) as a new drug for the treatment of substance use disorders in animal models. The results show that BCP can prevent or reverse behavioral changes resulting from drug exposure. The mechanism involves activation of the CB2 receptor and potentially other targets. Further research, including studies in humans, is needed to establish its therapeutic potential and mechanisms of action.
CURRENT NEUROPHARMACOLOGY
(2023)
Review
Neurosciences
Lais B. Martins et al.
Summary: This study aims to provide a comprehensive overview of the involvement of the kynurenine pathway (KP) in the pathophysiology of Alzheimer's disease (AD) and Parkinson's disease (PD) and discuss potential therapeutic opportunities. The results showed altered levels of KP metabolites in the brains of AD and PD patients, and associations between peripheral levels of KP metabolites and cognitive function in these patients.
CURRENT NEUROPHARMACOLOGY
(2023)
Review
Neurosciences
Suelyn Koerich et al.
Summary: Advanced glycation end products (AGEs) are compounds formed by the non-enzymatic addition of reducing sugars to lipids, proteins, and nucleic acids. They are associated with clinical complications in diabetes, cardiovascular diseases, and neurodegenerative diseases. The receptor for advanced glycation end-products (RAGE) is a key target for pharmacological interventions in neurodegenerative diseases. This review discusses the effects of AGEs and RAGE activation in the pathophysiology of neurodegenerative diseases, as well as potential pharmacological tools and drug candidates.
CURRENT NEUROPHARMACOLOGY
(2023)
Article
Multidisciplinary Sciences
Meredith A. Mortberg et al.
Summary: Neurodegenerative disease trials have become more selective, but the potential for early intervention against root molecular causes of disease remains largely unexplored.
SCIENTIFIC REPORTS
(2022)
Review
Neurosciences
Tommaso Schirinzi et al.
REVIEWS IN THE NEUROSCIENCES
(2020)
Editorial Material
Clinical Neurology
Nils Erik Gilhus et al.
NATURE REVIEWS NEUROLOGY
(2019)
